Volume finally picked up at end of day; seen this before but then no follow through; should get a good idea, however of progress 907 is making towards curing refractory/relapsed DLBCL patients on September 9th.
I took the schedule off Curis' second quarter earnings release by going to its website and looking under "financials/information." In the written release, there is a section entitled "Upcoming Activities" and these presentations were listed. It said it "expects" to present at these conferences.
No volume on this stock, but should learn a lot over next four months; announcement of pivotal trial regarding refractory/relapsed DLBCL patients coupled with solid results regarding phase 1B at ASH in early December would make for a nice holiday. GO CRIS GO! Stay tuned for upcoming events:
Robert W. Baird & Co. 2015 Health Care Conference, September 9-10, 2015 in New York City
• FBR 2nd Annual Healthcare Conference, September 9, 2015 in Boston, MA
• 14th Annual BIO Investor Forum, October 20-21, 2015 in San Francisco
Doomsayer, what are you doing today? dumping the stock you own, selling the stock short or just doomsaying? Are the Baker Brothers about to get wiped out? How long before the "Big money" pulls out and sends the stock to .50? Is Forbes in on the cabal to keep the price artificially high by stating chances are strong that Curis will be bought out or partner with a big pharma company regarding 907?
Doomsayer, I was on vacation last week and missed your call for the price to drop to .50 cents. Are you dumping the stock today? Are you shorting it? Please advise so I will know what to do.
the stock is headed down, I think it stays above $2 due to the announcement of the IND filing this fall; apparently medical presentations coincide with the announcement. 907 is taking forever and is looking like Erivdege, relevant to a small population of cancer patients, assuming it ever gets to market. Stock is off a dollar from its high of $3.75.
Nothing out of the ordinary, pretty much given up on 427; an awful lot of tinkering going on with 907; so momentary euphoria getting the stock as high as $3.75 is over, stock down below $3 with no incipient catalysts to turn it around. At the end of conference call CEO thanked his employees and investigators for their hard work, should have thanked the long term investors for remaining loyal; clearly one of my worse investments so far.
A subset of medulloblastoma tumors briefly stopped growing or disappeared entirely during treatment with vismodegib; St. Jude Children’s Hospital led the Pediatric Brain Tumor Consortium trials in children and adults.
Memphis, Tennessee, July 29, 2015
Giles W. Robinson, MD
A targeted therapy already used to treat advanced skin cancer is also effective against the most common subtype of the brain tumor medulloblastoma in adults and should be considered for treatment of newly diagnosed patients, according to research led by St. Jude Children’s Research Hospital.
1. Curis has met with FDA regarding an end of study meeting regarding its orphan candidate for DLBCL patients; enrollment will commence for phase 2 in September.
2. Phase 1 combination study with Rituxan and 907 shows solid preliminary results.
3. Phase 1 solid tumor trial results shows promise of 907's broader application.
4. IND filing for PD-L1/PD-1 inhibitor is imminent.
agreed; as was the volume during the recent rise an indication of a false start; been following this stock for more than a decade; the volume was huge when FDA approved Erivedge. No fun seeing it fall off today; but news is coming maybe not as significant as the FDA'a approval of Erivedge, but if it is positive results showing CUDC-907's likelihood of FDA approval in coming years, then the price will stay above 3. Any indication the Aurigene molecules show promise would bring alot of attention to Curis. There should be news coming in September through November on several fronts; and the conference call for the second quarter should occur during the first week in August at which time we should learn about the status of the second phase regarding the current 907 orphan drug trial.
As the Curis historian, having followed and owned this stock on and off, now on, since 1999, I believe history shows that most of the comments on this board amount to gibberish. As far as Curis goes, I believe it has got to get CUDC-907 to market for treatment of refractory/relapsed LDBCL patients. More important, it needs to show its Aurigene molecule has a place in the immunotherapy competition to treat cancer. It is news that drives small biotechs, pure and simple, and we should hear by early August whether Curis shows promise of getting 907 to market after its incipient phase 2 stage, just as Genetech did with Erivedge.
Is now the time to dump? I did not follow your advice on June 28th. Are you still dumping on July 1st?
when he did mention checkpoint inhibitors, my eyes lit up especially when he indicated this was another way of utilizing immunotherapy to attack cancer cells. Even though Curis is late to the game, as I understand its molecule, it is orally administered which would represent a significant cost savings relative to the competition that is relying on infusion. The announcement of the IND application should get investors' attention although too early to put a value on this drug. Hopefully, CUDC-907's progress will fill the void.
Jun 18, 2015
3:35 PM ET
13th International Congress on Malignant Lymphoma - Younes is speaking now, maybe his oral presentation will shed further light on progress of CUDC-907. I do believe Curis is in the lead in terms of treating refractory/relapsed DLBCL patients; nothing in immunotherapy has targeted this advanced cancer. Hopefully Curis is meeting with FDA soon to start its phase 2 trial.
It was a great run from $1.30 on January 8th to $3.65 the past week. Not expecting much impactful news until November at the earliest. Is there anyway to get a handle on Curis' incursion into immune-oncology? I am assuming like Erivedge, and now CUDC-907, it will take a long time before the market puts any value on the development of either PD-L1 or IRAK4. See stock falling back to $3; hopefully the announcement of CUDC-907's progression to Phase 2 will get the stock to move back up.
thanks that was helpful, maybe the release of preliminary data on phase 1 solid tumor trial will be impressive. We are back to a wait and see approach.
Longs are going to have to be patient as not sure we will hear any more news in 2015 that will move the stock. Curis should announce start of 907 phase 2 by November, but do not see how that affects price. Announcing of IND for PD-L1 immune-oncology candidate should not make a wave as it will be years before we know if that investment pays off. Only hope is that tech savvy guns working for the big pharms who look for small bios to takeover before their drugs get approved see something in Curis' pipeline. First Eagle must know something; it has been long for over a decade, and Fidelity's recent purchase holds promise. In meantime I expect price to drift lower to $3, but obviously I hope I am wrong.